1. Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
- Author
-
Jong Mu Sun, Jinseon Yoo, Kyoung Ho Pyo, Byoung Chul Cho, Se-Heon Kim, Sun Ock Yoon, Hye Ryun Kim, Dong Min Jung, Yoon Woo Koh, Eun Chang Choi, Han Na Kang, Hyo Sup Shim, Kyu Ryung Kim, Kwon Young Ju, Tae Min Kim, Han Sang Kim, Soonmyung Paik, Jae Woo Choi, Min Hee Hong, Mi Ran Yun, Myoung Ju Ahn, and Jinna Kim
- Subjects
Male ,Oncology ,Cancer Research ,Buparlisib ,Aminopyridines ,Cetuximab ,Apoptosis ,Mice, SCID ,Mice ,chemistry.chemical_compound ,0302 clinical medicine ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Head and neck cancer ,Head and neck ,Aged, 80 and over ,0303 health sciences ,Middle Aged ,Progression-Free Survival ,Up-Regulation ,Treatment Outcome ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,DNA Copy Number Variations ,Combination therapy ,Cell Survival ,Morpholines ,Mice, Nude ,Article ,03 medical and health sciences ,Internal medicine ,Animals ,Humans ,Basal cell ,Aged ,030304 developmental biology ,Whole Genome Sequencing ,Squamous Cell Carcinoma of Head and Neck ,business.industry ,Gene Expression Profiling ,Reproducibility of Results ,Cancer ,Cell Cycle Checkpoints ,medicine.disease ,Clinical trial ,chemistry ,Drug Resistance, Neoplasm ,Mutation ,business ,Neoplasm Transplantation - Abstract
Background Recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) is a common cancer with high recurrence and mortality. Current treatments have low response rates (RRs). Methods Fifty-three patients with R/M SCCHN received continuous oral buparlisib. In parallel, patient-derived xenografts (PDXs) were established in mice to evaluate resistance mechanisms and efficacy of buparlisib/cetuximab combination. Baseline and on-treatment tumour genomes and transcriptomes were sequenced. Based on the integrated clinical and PDX data, 11 patients with progression under buparlisib monotherapy were treated with a combination of buparlisib and cetuximab. Results For buparlisib monotherapy, disease control rate (DCR) was 49%, RR was 3% and median progression-free survival (PFS) and overall survival (OS) were 63 and 143 days, respectively. For combination therapy, DCR was 91%, RR was 18% and median PFS and OS were 111 and 206 days, respectively. Four PDX models were originated from patients enrolled in the current clinical trial. While buparlisib alone did not inhibit tumour growth, combination therapy achieved tumour inhibition in three of seven PDXs. Genes associated with apoptosis and cell-cycle arrest were expressed at higher levels with combination treatment than with buparlisib or cetuximab alone. Conclusions The buparlisib/cetuximab combination has significant promise as a treatment strategy for R/M SCCHN. Clinical Trial Registration NCT01527877.
- Published
- 2020
- Full Text
- View/download PDF